AffaMed Therapeutics, a global clinical-stage biopharmaceutical company, has raised over $170 million in Series B financing. Lake Bleu Capital led the round with participation from other investors that included Partners Investment, Superstring Capital, Orion Science Capital, Fountainhead Partners and CBC Group.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: